Cellectricon has signed a license agreement with Fluicell AB, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights.
The Dynaflow Resolve system is considered by many, to be the premier secondary ion channel screening platform on the market, offering high time resolution for any cell type, any ion channel, and in any patch clamp configuration. Launched in 2004, the Dynaflow platform is an established product with a global user base within big pharma and biotech companies. The Dynaflow platform is complementary to Fluicell´s BioPen system for single-cell-based discovery using optical readouts such as fluorescence microscopy. Both are state-of-the art microfluidic-based technologies which appeal to discerning medical, biology and pharma professionals worldwide, that wish to get the most out of their experiments.Read more
Cellectricon continues to grow and we are now looking to fill two positions; an assay development and screening scientist and a laboratory assistant.
The employments offers exciting opportunities to provide important support to our ongoing customer projects. Learn more about Cellectricon and the two positions on our Careers page.Read more
Date: Nov 11, 2017
Presentation Time: 1:00 pm – 2:00 pm
Presentation Number: 039.09
Poster Board Number: D58
Modulators of synaptic transmission, acting at various molecular targets, have great potential for development as novel therapeutic agents in an extensive range of CNS diseases, and the search for novel specific pharmacological agents is of widespread interest. However, traditional high throughput screening approaches primarily rely on heterologous expression systems which lack the ability to replicate synaptic complexity. Thus there is a need to develop screening systems that can evaluate compounds on measures of synaptic transmission.
Date: Nov 14, 2017
Presentation Time: 9:00 am – 10:00 am
Presentation Number: 486.14
Poster Board Number: AA9
Physiologically relevant human models of chronic pain are essential to developing new therapeutics and overcome poor translation between animal studies and the clinical setting. We therefore developed a humanized screening assay with sensory neurons derived from human induced pluripotent stem cells (hiPSCs). The resulting assay can be applied in screening to identify compounds that change a disease phenotype, such as neuronal excitability, rather than the activity of specific targets.
Date: Nov 15, 2017
Presentation Time: 4:00 pm – 5:00 pm
Presentation Number: 767.28
Poster Board Number: AA12
Progress in developing higher throughput assays for peripheral pain has largely been limited by the lack of disease-relevant human neuronal cultures. However, with the advent of the human induced pluripotent stem cell (hiPSC) technology, human sensory-like neurons can now be produced in sufficient volumes to enable plate based screening.